These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 38892472)

  • 21. Breast Cancer: Current Molecular Therapeutic Targets and New Players.
    Nagini S
    Anticancer Agents Med Chem; 2017; 17(2):152-163. PubMed ID: 27137076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triple Negative Breast Cancer: A Tale of Two Decades.
    Ali AM; Ansari JAK; El-Aziz NMA; Abozeed WN; Warith AMA; Alsaleh K; Nabholtz JM
    Anticancer Agents Med Chem; 2017; 17(4):491-499. PubMed ID: 27456662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New targets for triple-negative breast cancer.
    Herold CI; Anders CK
    Oncology (Williston Park); 2013 Sep; 27(9):846-54. PubMed ID: 24282978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent advancement in developing small molecular inhibitors targeting key kinase pathways against triple-negative breast cancer.
    Islam R; Yen KP; Rani NN'M; Hossain MS
    Bioorg Med Chem; 2024 Oct; 112():117877. PubMed ID: 39159528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.
    Roberts MS; Anstine LJ; Finke VS; Bryson BL; Webb BM; Weber-Bonk KL; Seachrist DD; Majmudar PR; Keri RA
    Breast Cancer Res; 2020 Jun; 22(1):66. PubMed ID: 32552913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Triple-negative breast cancer molecular subtyping and treatment progress.
    Yin L; Duan JJ; Bian XW; Yu SC
    Breast Cancer Res; 2020 Jun; 22(1):61. PubMed ID: 32517735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent advances in targeted strategies for triple-negative breast cancer.
    Zhu S; Wu Y; Song B; Yi M; Yan Y; Mei Q; Wu K
    J Hematol Oncol; 2023 Aug; 16(1):100. PubMed ID: 37641116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent Advances in Immunotherapy and Targeted Therapy of Triple Negative Breast Cancer.
    Shewale H; Kanugo A
    Curr Pharm Biotechnol; 2024 Jul; ():. PubMed ID: 39092645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
    Costa RLB; Han HS; Gradishar WJ
    Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of novel small molecules targeting the USP21/JAK2/STAT3 axis for the treatment of triple-negative breast cancer.
    Long L; Xu J; Qi X; Pen Y; Wang C; Jiang W; Peng X; Hu Z; Yi W; Xie L; Lei X; Wang Z; Zhuo L
    Eur J Med Chem; 2024 Jul; 273():116500. PubMed ID: 38776807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway.
    Massihnia D; Galvano A; Fanale D; Perez A; Castiglia M; Incorvaia L; Listì A; Rizzo S; Cicero G; Bazan V; Castorina S; Russo A
    Oncotarget; 2016 Sep; 7(37):60712-60722. PubMed ID: 27474173
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.
    Brand TM; Iida M; Dunn EF; Luthar N; Kostopoulos KT; Corrigan KL; Wleklinski MJ; Yang D; Wisinski KB; Salgia R; Wheeler DL
    Mol Cancer Ther; 2014 May; 13(5):1356-68. PubMed ID: 24634415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies.
    Medina MA; Oza G; Sharma A; Arriaga LG; Hernández Hernández JM; Rotello VM; Ramirez JT
    Int J Environ Res Public Health; 2020 Mar; 17(6):. PubMed ID: 32245065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasis.
    Paul A; Gunewardena S; Stecklein SR; Saha B; Parelkar N; Danley M; Rajendran G; Home P; Ray S; Jokar I; Vielhauer GA; Jensen RA; Tawfik O; Paul S
    Cell Death Differ; 2014 Sep; 21(9):1469-81. PubMed ID: 24786829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel combinatorial autophagy inhibition therapy for triple negative breast cancers.
    Abd El-Aziz YS; Toit-Thompson TD; McKay MJ; Molloy MP; Stoner S; McDowell B; Moon E; Sioson L; Sheen A; Chou A; Gill AJ; Jansson PJ; Sahni S
    Eur J Pharmacol; 2024 Jun; 973():176568. PubMed ID: 38604544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Triple-Negative Breast Cancer: The Progress of Targeted Therapies and Future Tendencies.
    Damaskos C; Garmpi A; Nikolettos K; Vavourakis M; Diamantis E; Patsouras A; Farmaki P; Nonni A; Dimitroulis D; Mantas D; Antoniou EA; Nikolettos N; Kontzoglou K; Garmpis N
    Anticancer Res; 2019 Oct; 39(10):5285-5296. PubMed ID: 31570423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.
    Merrouche Y; Fabre J; Cure H; Garbar C; Fuselier C; Bastid J; Antonicelli F; Al-Daccak R; Bensussan A; Giustiniani J
    Oncotarget; 2016 Aug; 7(33):53350-53361. PubMed ID: 27462789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1α-/VEGF-signaling.
    von Wahlde MK; Hülsewig C; Ruckert C; Götte M; Kiesel L; Bernemann C
    Gynecol Endocrinol; 2015 Feb; 31(2):160-4. PubMed ID: 25356777
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer.
    Jain V; Kumar H; Anod HV; Chand P; Gupta NV; Dey S; Kesharwani SS
    J Control Release; 2020 Oct; 326():628-647. PubMed ID: 32653502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.